Axitinib: A Next Generation VEGFR inhibitor for Metastatic Renal Cell Cancer

Rob Zielinski, MBBS, and Christian Kollmannsberger, MD

British Columbia Cancer Agency, Vancouver, BC, Canada

Pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) and its receptors, are important regulators of tumor angiogenesis, survival, and metastasis, and are overexpressed in renal cell carcinoma (RCC). There is a plethora of US Food and Drug Administration (FDA)-approved agents for advanced RCC that inhibit circulating VEGF or its targets, the VEGF-receptors (VEGFRs).

Riluzole and Amyotrophic Lateral Sclerosis

Luc Dupuis, PhD1,2,3,4, Albert C Ludolph MD3, and Vincent Meininger MD4,5

1Inserm U692; 2Université de Strasbourg, Faculté de Médecine, UMRS692, Strasbourg, France; 3Department of Neurology, Ulm University, Ulm, Germany; 4Département des Maladies du Système Nerveux, Centre Référent Maladie Rare SLA Hôpital de la Pitié-Salpêtrière (AP-HP); 5Université Pierre et Marie Curie, Paris, France

Almost 20 years after the first positive clinical trial, riluzole remains the only drug with proven efficacy in increasing survival in patients with amyotrophic lateral sclerosis (ALS).

Teriflunomide for Multiple Sclerosis

Jiwon Oh, MD, FRCPC1,2, and Paul W O’Connor, MD, MSc, FRCPC1

1Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; 2Department of Medicine, Division of Neurology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada.

A number of oral agents are under development and investigation for use in the treatment of multiple sclerosis (MS). Among these experimental agents, teriflunomide is showing promise with respect to safety and clinical efficacy in relapsing MS patients.

1 2 3




Latest News

Latest Articles

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home